DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
The use of proteasome inhibitors and immunomodulatory drugs in the clinical practice has contributed to the significant improvement in survival for patients with multiple myeloma over the past decades. Alongside this, due to the recurrent course of the disease, there is a need to introduce new class...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
Remedium Group LLC
2017-11-01
|
| Edice: | Медицинский совет |
| Témata: | |
| On-line přístup: | https://www.med-sovet.pro/jour/article/view/2173 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|